Arrowhead Pharmaceuticals, Inc. (ARWR) 2013年年度报告「NASDAQ」.pdf

1、 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,DC 20549 FORM 10-K (Mark One)ANNUAL REPORT UNDER SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended September 30,2013.TRANSITION REPORT UNDER SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the tr

2、ansition period from to Commission file number 000-21898 ARROWHEAD RESEARCH CORPORATION(Exact name of registrant as specified in its charter)Delaware 46-0408024(State of incorporation)(I.R.S.Employer Identification No.)225 S.Lake Avenue,Suite 1050Pasadena,California 91101(626)304-3400(Address and te

3、lephone number of principal executive offices)Securities registered under Section 12(b)of the Exchange Act:Title of each class Name of each exchange on which registeredCommon Stock,$0.001 par value The NASDAQ Capital MarketSecurities registered pursuant to Section 12(g)of the Exchange Act:None Indic

4、ate by a check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No Indicate by a check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d)of the Act.Yes No Indicate by check mark whether the registrant(1)has fi

5、led all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(orfor such shorter period that the registrant was required to file such reports),and(2)has been subject to such filing requirements for the past 90 days.Yes No Indicate by

6、 check mark whether the registrant has submitted electronically and posted on its corporate Web site,if any,every Interactive Data File required to be submitted and postedpursuant to Rule 405 of Regulation S-T during the preceding 12 months(or for such shorter period that the registrant was required